How do I verify if a tissue vendor is registered with the FDA?

You can verify a tissue supplier by searching the FDA Human Cell and Tissue Establishment Registration (HCTERS) public database. Request the vendor's FEI (Facility Establishment Identifier) number and confirm that their registration is active and lists the specific tissue types they process or distribute.

What is the difference between Section 361 and Section 351 tissue products?

Section 361 HCT/Ps are minimally manipulated tissues intended for homologous use that do not require pre-market approval. Section 351 products involve more than minimal manipulation or non-homologous uses, making them biological drugs that require FDA Investigational New Drug (IND) applications or approved Biologics License Applications (BLA).

What documentation must accompany every allograft shipment?

Every allograft shipment must include a Summary of Records (SoR) confirming donor eligibility screening and testing, a Certificate of Analysis (CoA) verifying lot sterility and safety parameters, and package tracking labels for chart documentation.

What temperature monitoring is required for cryopreserved allografts?

Cryopreserved tissue allografts typically require continuous storage at -80°C or colder. Practices should maintain dedicated ultra-low temperature freezers equipped with calibrated, continuous temperature data loggers and automated alarm systems to alert staff of temperature excursions.

Vendor Vetting Checklist for FDA Compliant Tissue Allografts

A rigorous vendor vetting checklist for FDA compliant tissue allografts evaluates manufacturer 21 CFR 1271 establishment registration, donor screening records, terminal sterilization methods, and documented cold-chain protocols. Auditing these critical quality controls protects practices against non-compliant HCT/Ps while ensuring operational transparency and consistent performance across all biologics procurement workflows.

Regulatory Baseline: 21 CFR 1271 and HCT/P Compliance

Under the U.S. Food and Drug Administration (FDA) framework, human tissue products are regulated under Title 21 of the Code of Federal Regulations (CFR) Part 1271. Tissue processors and distributors must comply with Current Good Tissue Practice (cGTP) requirements to prevent the introduction, transmission, or spread of communicable diseases.

When evaluating a supplier or manufacturer, practice managers must understand the critical regulatory distinction between Section 361 and Section 351 products:

Section 361 HCT/Ps: Governed strictly under 21 CFR 1271, these products are minimally manipulated, intended for homologous use, and do not combine tissue with another drug or device. They do not require pre-market approval (BLA) if they meet all criteria under 21 CFR 1271.10.
Section 351 Products: Tissue products that undergo more than minimal manipulation or are promoted for non-homologous uses are regulated as biological drugs. These require an Investigational New Drug (IND) application or an approved Biologics License Application (BLA) prior to commercial marketing.

Procuring products from vendors that misclassify Section 351 products as Section 361 tissue allografts exposes practices to significant legal and operational risk. Practice managers must demand complete regulatory transparency before adding any biologic to clinical inventory.

Comprehensive Vendor Vetting Checklist for Tissue Allografts

Practice administrators should maintain a dedicated vendor compliance file for every biologic distributor and manufacturer. Use the following structured checklist during initial evaluation and annual vendor audits:

1. Regulatory Registration and Licensure

[ ] FDA Establishment Registration: Obtain the vendor's active FDA Registration Number (FEI) and confirm active listing on the FDA Human Cell and Tissue Establishment Registration database.
[ ] State Licensing: Verify that the supplier and primary processing facility hold valid tissue bank licenses in your state, if required (e.g., Texas, California, New York, Florida).
[ ] Accreditation: Check for current accreditation by the American Association of Tissue Banks (AATB) or equivalent recognized quality bodies.

2. Donor Screening and Testing Protocols

[ ] Donor Eligibility Documentation: Confirm that every lot includes a Summary of Records (SoR) certifying donor screening compliance under 21 CFR 1271.75.
[ ] CLIA-Certified Testing: Ensure donor blood samples are tested in CLIA-certified laboratories using FDA-licensed screening tests.
[ ] Infectious Disease Panel: Verify testing for HIV-1/2, Hepatitis B (HBsAg and anti-HBc), Hepatitis C (anti-HCV), Syphilis, and HTLV I/II, along with Nucleic Acid Testing (NAT) for relevant pathogens.

3. Manufacturing and Quality Assurance

[ ] cGTP Compliance: Confirm written Standard Operating Procedures (SOPs) for processing, packaging, handling, and storage.
[ ] Sterilization Validation: Review whether the tissue undergoes terminal sterilization (e.g., gamma irradiation, e-beam) or aseptic processing, and verify the Sterility Assurance Level (SAL 10^-6 for terminally sterilized tissue).
[ ] Third-Party Testing: Request Certificate of Analysis (CoA) documentation per lot, confirming sterility, endotoxin levels, and structural safety.

4. Supply Chain and Logistics Controls

[ ] Cold-Chain Tracking: Review shipping procedures, including validated dry ice or liquid nitrogen containers and calibrated temperature data loggers.
[ ] Storage Specifications: Confirm clear storage parameters (e.g., ambient, -20°C, or -80°C cryopreservation) and required freezer specifications.
[ ] Lot Traceability System: Verify that packaging includes standardized tissue tracking labels (ISBT 128 or equivalent) for seamless inclusion in patient medical records.

Operational vs. Clinical Perspectives in Procurement

Successful procurement of tissue allografts requires alignment between the administrative team managing risk and the clinical team delivering patient care. Each perspective prioritizes distinct aspects of vendor selection.

The Operational Perspective (Practice Administrator / Procurement Manager)

For administrative leaders, tissue procurement directly impacts cost structure, workflow efficiency, and compliance liability. Key operational priorities include:

Total Cost of Acquisition: Evaluating per-unit pricing, shipping fees, minimum order quantities, and consignment options to protect cash flow.
Reimbursement vs. Cash-Pay Models: Aligning product selection with practice billing structures, whether utilizing specific HCPCS codes for covered surgical procedures or cash-pay cash flows in cash-based specialties.
Risk Mitigation: Ensuring comprehensive vendor product liability insurance coverage and indemnity protection for the clinical practice.
Inventory Overhead: Managing shelf-life limitations and specialized equipment costs (such as dedicated -80°C freezers and monitored alert systems).

Practices reviewing high-quality biologics, custom compounding support, and regenerative options can explore our full range of compliant biologics solutions.

The Clinical Perspective (Treating Clinician / Medical Director)

For treating physicians—such as those operating in pain management clinics, sports medicine, or orthopedic care—the focus remains squarely on biological safety and functional efficacy:

Structural and Tissue Integrity: Ensuring the processing method preserves necessary ECM components, collagen structure, and native tissue scaffolding without damaging non-viable biological factors.
Handling and Usability: Assessing hydration times, flowability for injection, graft handling characteristics, and surgical delivery format.
Sterility and Safety: Demanding absolute confidence in terminal sterilization and low endotoxin profiles to minimize post-procedure inflammatory reactions.

Supply Chain, Cold-Chain Integrity, and Lot Traceability

Maintaining cold-chain integrity from the donor facility to the patient treatment room is a critical aspect of tissue allograft compliance. Thermal exposure outside validated parameters can compromise structural tissue stability and negate sterile handling procedures.

When receiving allograft shipments, clinical personnel must perform immediate intake procedures:

Inspect outer packaging and insulated shipping containers for damage.
Check temperature indicators or data loggers to verify temperature was maintained throughout transit.
Match serial numbers and lot numbers on the vial/package against the packing slip and Summary of Records.
Log the tissue immediately into the facility's tissue tracking register, detailing receipt date, lot number, expiration date, and storage location.
Store tissue in dedicated, monitored storage units that meet manufacturer temperature specifications.

Reviewing distributor transparency and quality controls is essential; practices can learn more about regulatory commitments on our about page.

What This Means for Your Practice

Implementing a robust vetting process protects your practice legally, financially, and clinically. To establish compliant procurement workflows today, complete these action steps:

Audit Current Biologic Inventory: Review all active tissue allografts in your practice against your state and FDA registration database.
Request Full Compliance Packets: Contact current vendors to request updated FDA Form 3488 listings, state licenses, certificates of analysis, and sample donor summaries.
Standardize Intake Protocols: Establish a mandatory biological intake checklist for your clinical staff to record lot numbers and storage temperatures upon package arrival.
Update Traceability Logs: Ensure every patient chart includes the tissue lot number, expiration date, and manufacturer details to satisfy state tissue banking audit requirements.

For common questions regarding tissue procurement, storage standards, and regulatory compliance, visit our FAQ section.

Partnering with a Compliant Tissue Distributor

Navigating tissue procurement requires a partner dedicated to strict FDA compliance, continuous supply chain verification, and clinical support. Dallas Regenerative Solutions supplies licensed providers with thoroughly vetted biological products, advanced clinical devices, and ongoing operational education.

To speak with a specialist about auditing your biologic vendor compliance or selecting compliant allografts for your practice, contact us today to schedule a clinical consultation.